Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

100
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
100
Cardiac Catheterization II: Right Heart Catheterization01:21

Cardiac Catheterization II: Right Heart Catheterization

68
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Italian multicentre registry for Mechanically Assisted Circulatory Support (ITAMACS) report: 12-year experience of over 1000 durable LVAD patients.

European journal of heart failure·2026
Same author

Suitability of sedative usage in patients undergoing cardiovascular surgery.

Expert review of cardiovascular therapy·2026
Same author

Author Correction: Remimazolam for ICU sedation: a genuine advance or a familiar story?

Intensive care medicine·2026
Same author

Remimazolam for ICU sedation: a genuine advance or a familiar story?

Intensive care medicine·2026
Same author

Pressure-Volume-Derived Ventricular Energetics Across Mechanical Circulatory Support Strategies in Cardiogenic Shock.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Impact of Partial- to Full-Support Escalation With Microaxial Flow Pumps Prior to Durable Left Ventricular Assist Device Implantation.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026

Related Experiment Video

Updated: Jul 31, 2025

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

729

Four-Factor Prothrombin Complex Concentrate in Left Ventricular Assist Device Implantation: Inverse Propensity

Fabrizio Monaco1, Margherita Licheri1, Gaia Barucco1

  • 1From the Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.

ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|May 5, 2023
PubMed
Summary

Four-factor prothrombin complex concentrates (PCCs) did not reduce major bleeding or blood product transfusions in patients undergoing left ventricle assist device (LVAD) implantation compared to fresh frozen plasma (FFP). Safety outcomes were similar between the two hemostatic agents.

More Related Videos

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

847
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Related Experiment Videos

Last Updated: Jul 31, 2025

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

729
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

847
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Area of Science:

  • Cardiology
  • Hematology
  • Surgical Innovation

Background:

  • Managing coagulopathy during left ventricle assist device (LVAD) implantation is critical.
  • Fresh frozen plasma (FFP) is a standard hemostatic agent, but alternatives are being explored.
  • Four-factor prothrombin complex concentrates (PCCs) offer a concentrated source of clotting factors.

Purpose of the Study:

  • To compare the efficacy of intraoperative four-factor PCCs versus FFP in reducing major bleeding and blood product transfusions.
  • To assess complications and survival rates associated with PCCs versus FFP in LVAD recipients.
  • To evaluate the hemostatic effectiveness of PCCs as a first-line agent in this patient population.

Main Methods:

  • A comparative study of 138 patients undergoing LVAD implantation.
  • 32 patients received four-factor PCCs, while 102 received FFP as the primary hemostatic agent.
  • Analysis included crude estimates and inverse probability of treatment weighting (IPTW) adjusted models.

Main Results:

  • The PCC group required more FFP intraoperatively and at 24 hours post-surgery.
  • The PCC group also showed a trend towards increased packed red blood cell (RBC) transfusions at 24 and 48 hours.
  • No significant differences were observed in adverse events or survival between the PCC and FFP groups.

Conclusions:

  • Intraoperative four-factor PCCs were not associated with a reduction in major bleeding or blood product transfusions compared to FFP.
  • PCCs demonstrated a similar safety profile regarding thrombotic events.
  • FFP remains a viable option for hemostasis in LVAD implantation, with PCCs not showing a clear advantage in this study.